Vibrio cholerae O1 from Accra, Ghana carrying a class 2 integron and the SXT element by Opintan, Japheth A. et al.
Vibrio cholerae O1 from Accra, Ghana carrying a class 2 integron
and the SXTelement
Japheth A. Opintan1, Mercy J. Newman1, Owusu Agyemang Nsiah-Poodoh1
and Iruka N. Okeke2*
1Department of Microbiology, University of Ghana Medical School, PO Box 4236, Accra, Ghana;
2Department of Biology, Haverford College, 370 Lancaster Avenue, Haverford, PA 19041, USA
Received 16 May 2008; returned 16 June 2008; revised 24 July 2008; accepted 25 July 2008
Objectives: Vibrio cholerae O1 from a 2006 outbreak in Accra were commonly resistant to multiple anti-
microbials and, in particular, to trimethoprim/sulfamethoxazole, drugs commonly used in the treatment
of cholera. We sought to determine the genetic basis for trimethoprim/sulfamethoxazole resistance in
outbreak isolates.
Methods: Twenty-seven isolates from the outbreak were screened by PCR and sequencing for class 1
and 2 integrons and for the SXT element.
Results: Twenty-one of the 27 isolates examined, all from the Accra metropolitan area, carried both SXT,
an integrated chromosomal element, and a class 2 integron bearing dfrA1, sat and aadA1 cassettes.
All these isolates had identical random ampliﬁcation of polymorphic DNA proﬁles and two of them also
carried a class 1 integron.
Conclusions: Most strains characterized carried multiple elements conferring resistance to trimethoprim.
This suggests that trimethoprim/sulfamethoxazole should not be used empirically in cholera treatment.
Keywords: trimethoprim resistance, antimicrobial resistance, antibiotic resistance, cholera
Introduction
Cholera is an acute diarrhoeal disease caused by Vibrio cholerae
O1 or O139. Cholera epidemics spread rapidly and, without
intervention, can lead to death due to dehydration. In 2006,
98.9% of the cholera cases reported worldwide, and all but 8
of the 6311 deaths, were reported from Africa.
1 Angola, the
Democratic Republic of Congo, Ethiopia and Sudan were the
worst-hit countries, but most coastal West African countries
reported large numbers of cases and case fatality rates of 1% to
6.2%. Between 2 January and 25 June 2006, 1869 cases and 79
deaths (a 4.2% case fatality rate) were reported in Ghana. By the
end of the year, the count was 3357 cases and 107 deaths, with
an overall case fatality rate of 3.19%.
1
Antimicrobials are not required to manage cholera, but they
shorten the duration and reduce the severity of the disease,
curbing transmission. Thus, antimicrobial resistance can increase
the outbreak size, duration and case fatality rates. Tetracycline
was originally the antimicrobial of choice for cholera and
was used widely in Africa until resistance to the drug conferred
by incompatibility group C plasmids became common.
Subsequently, trimethoprim/sulfamethoxazole, ampicillin and
quinolones have been used, but resistance to these and other
drugs has been reported (reviewed by Okeke et al.
2).
Although Africa bears much of the present-day burden of
cholera,
1,3 very little is known about strain susceptibility, particu-
larly in West Africa. In 2000, Dalsgaard et al.
4 described a
V. cholerae multiresistance plasmid, bearing a class 1 integron from
Guinea-Bissau. There have been other reports of antimicrobial-
resistant V. cholerae from West Africa, but none have under-
taken molecular analysis to identify speciﬁc resistance genes and
dissemination mechanisms.
5,6 In contrast, multiple studies from
outbreaks in southern and eastern Africa elucidate the molecular
basis for resistance in V. cholerae,
7–11where resistance has been
increasingly common in recent years and has largely been
associated with strains carrying resistance cassettes in class 1
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strains carrying a resistance-conferring integrated chromosomal
element known as the SXT element have also emerged.
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Materials and methods
Strains
We studied antimicrobial resistance in 27 isolates from the January
to June 2006 outbreak that occurred in Ghana. The strains were
isolated from patients at 14 different locations.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed according to the
disc diffusion method described by the CLSI (formerly the
NCCLS)
13 and using Escherichia coli NCTC 10418 as a control.
Wild-type V. cholerae isolates were screened for resistance to
trimethoprim/sulfamethoxazole, amikacin, ceftazidime, ceftriaxone,
cefotaxime, chloramphenicol, gentamicin, tetracycline, nalidixic
acid, cefuroxime and levoﬂoxacin at the University of Ghana
Medical School. Recombinant strains, in an E. coli background,
were tested against ampicillin, trimethoprim, streptomycin, chloram-
phenicol, sulphonamides, nalidixic acid and ciproﬂoxacin at the
molecular microbiology laboratory at Haverford College. The dia-
meter of inhibition zones was measured in milllimetres and inter-
preted according to the CLSI requirements.
13
Detection and characterization of resistance
genes and elements
V. cholerae genomic DNA was extracted using the Wizard genomic
extraction kit (Promega) according to manufacturer’s directions and
used to create a template of PCR reactions. The oligonucleotide
primer pair dfr1a, which ampliﬁes six dfrA a l l e l e sa sd e s c r i b e db y
Navia et al.,
14 was used to screen the strains for trimethoprim-resistant
dihydrofolate reductase genes. Enteroaggregative E. coli strain 17-2,
which carries dfrA1, was used as a positive control. Primers that
anneal to the 30 and 50 conserved ends of class 1 and class 2 integrons
were to amplify integron-borne cassettes, essentially according to the
methods described by Le ´vesque et al.
15 and White et al.
16 Integrated
cassette amplicons were cloned into pGEMT (Promega) and
sequenced, and their MboIa n dAluI restriction fragment length
polymorphisms (RFLPs) were compared with sequenced amplicons.
Enteroaggregative E. coli strains 042 and 17-2, which carry an
aadA1-bearing class 1 integron and a dfrA1-sat-aadA1-bearing class 2
integron, respectively, were used as positive controls. The class 1
integron integrase gene (intI1) was identiﬁed using the primers
described by Leverstein-van Hall et al.,
17 and the SXT integrase gene
was detected by PCR, as described by Dalsgaard et al.
7
Random ampliﬁcation of polymorphic DNA
Strain relatedness was assessed by random ampliﬁcation of poly-
morphic DNA (RAPD), as described by Scrascia et al.,
18 employing
enterobacterial repetitive intergenic consensus primers (ERIC1 and
ERIC2).
Results
Biochemical and serological veriﬁcation revealed that all the
outbreak isolates were V. cholerae O1 serotype Ogawa, which is
commonly reported in Africa. As shown in Table 1, only 3 of
the 27 isolates were resistant to tetracycline, but all 27 strains
were resistant to other antimicrobials, 13 were resistant to 3 or
more of the 11 agents tested, and levoﬂoxacin was the only
tested drug to which all isolates were susceptible. We observed
nalidixic acid resistance in 10 isolates, and 26 of the 27 isolates
were resistant to trimethoprim/sulfamethoxazole.
Twenty-ﬁve of the 27 isolates produced a 0.47 kb amplicon
with the dfr1a primer pair that ampliﬁes dfrA1, dfrA5, dfrA15,
dfrA15b, dfrA16 or dfrA16b cassettes, but we did not amplify
cassette regions from class 1 integrons in any of the strains.
The class 1 integron integrase gene was, however, detected in
two strains, suggesting that these strains had very large variable
regions and/or a genetic modiﬁcation in the 30 or 50 conserved
ends recognized by the cassette-region primers of Le ´vesque
et al.
15 Importantly, the two class 1 integron-positive strains were
two of the three strains that were resistant to seven or more of the
antimicrobials tested (Table 1). However, although class 1 inte-
grons were associated with multiple resistance, they could not
account for most of the dfr cassettes detected. Screening for class
2 integron-borne cassettes produced a 2.2 kb product from control
strain 17-2 as well as from 22 V. cholerae isolates that produced
an amplicon with the dfr1a primers. The class 2 cassette-region
amplicon from strains V34 and V47 was directionally cloned into
pGEMT. The resulting clones were screened for resistance to
eight antimicrobials. Both were resistant to ampicillin (encoded
on the vector), trimethoprim and streptomycin, but susceptible to
chloramphenicol, sulphonamides, nalidixic acid and ciproﬂoxacin.
We sequenced the cloned amplicon from the strain V34 and
found that it contained three resistance gene cassettes, in the
commonly recovered context that is identical to that in strain
17-2: dfrA1-sat-aadA1. Strains that could, produced amplicons of
similar size; MboIa n dAluI RFLP patterns were also identical to
the patterns from strains V34, V47 and EAEC strain 17-2.
Primers for the SXT integrase gene were used to screen for
the SXT element, as described by Dalsgaard et al.
7 We obtained
a 0.6 kb amplicon, consistent with the expected size of 592 bp
produced by strains bearing the SXT element, in 24 strains. As
we did not have a positive control strain, we cloned the ampli-
con from the Ghanaian strain V34 into the vector pGEMT
(Promega) and sequenced it. The sequence obtained was 99%
identical to the SXT integrase in the GenBank database
(accession number AB114188.1).
Of the 27 isolates screened, 3 carried the SXT element alone,
one bore a class 2 integron with dfrA1-sat-aadA cassettes but
no SXT, and 21 strains possessed both elements. All strains
harbouring one or both elements showed high-level resistance
to trimethoprim/sulfamethoxazole and produced an amplicon
with the dfr1a primers. Of the two strains that were negative
for both elements, strain V111 was susceptible to trimethoprim/
sulfamethoxazole and strain V95 exhibited low-level resistance by
an unknown mechanism. All the strains that had neither or only
one of the two trimethoprim resistance-conferring elements were
recovered from patients from Awoshie, Agona Swedru, Ga West
and Tema, all of which are away from the Accra Metropolitan
area (Table 1). We additionally observed that although most of
the strains generated an identical RAPD proﬁle with ERIC2
primers, strains V95 and V111, both of which lacked the class 2
integron and the SXT element and were isolated from outside the
Accra Metropolitan area, produced distinctly different proﬁles
(Figure 1).
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Recently, resistant V. cholerae epidemics in Africa have impli-
cated class 1 integrons;
4,7,8 however, class 1 integrons were
detected in only two strains characterized in this study, both of
which were resistant to seven or more of the tested antimicro-
bials. In V. cholerae, resistant dihydrofolate reductase (dfr)
genes may also be part of a 62 kb transmissible integrated chro-
mosomal element, known as SXT.
19 In E. coli and closely
related organisms, resistant dfr cassettes are commonly associ-
ated with class 1 or class 2 integrons. Class 2 integrons have
only been recently reported from V. cholerae.
20 We elected to
screen the isolates for both class 2 integrons and the SXT-
integrated chromosomal element and found that most of the
isolates carried both elements.
Class 2 integrons identiﬁed in this study contained similar
cassettes as Tn7, a transposon commonly found in enteric organ-
isms, where it may be located on conjugative plasmids or
chromosomally integrated at a speciﬁc attachment site between
the pstS and glmS genes. Tn7-like elements have been found in
non-O1/O139 V. cholerae and other Vibrio spp., in which they
have been shown to be chromosomally integrated.
20 In this
study, we report the presence of a class 2 integron in V. cholerae
O1 Ogawa outbreak isolates, which have not been previously
reported in Africa.
The earliest reports of trimethoprim resistance in epidemic
V. cholerae O1 from Africa were associated with plasmid-borne
dfrA1 genes, most probably acquired from the gut micro-
ﬂora.
11,21 Laboratory studies and strain characterization in suc-
cessive outbreaks demonstrated that plasmid-borne resistance
genes are sometimes poorly expressed in V. cholerae and that
the plasmids were often not stably maintained in the absence of
resistance or that strains carrying them were less ﬁt and easily
displaced by susceptible strains.
10,22 In contrast, we found that
trimethoprim resistance is conferred by integrated chromosomal
elements, most strains evaluated in this study carried more than
Table 1. Antimicrobial resistance proﬁles and conferring genetic elements in 27 2006 V. cholerae O1 isolates from Accra
Strain Sex Age Location
Antimicrobial resistance
proﬁle
SXT
element
Class 1 integron
(intI1 gene)
Class 2
integron
Class 2 integron
cassettes
V112 m 3 Tema SXT þ 2 þ dfrA1-sat-aadA1
V42 m 47 Zongo SXT þ 2 þ dfrA1-sat-aadA1
V47 m 19 Nungua SXT þ 2 þ dfrA1-sat-aadA1
V51 m 6 Abuofu SXT þ 2 þ dfrA1-sat-aadA1
V52 m 34 Ayalolu SXT þ 2 þ dfrA1-sat-aadA1
V86 f 23 Agbogbloshie SXT þ 2 þ dfrA1-sat-aadA1
V97 m 60 Dangbe West SXT 22 þ dfrA1-sat-aadA1
V34 f 13 Accra SXT, NAL þ 2 þ dfrA1-sat-aadA1
V35 f 36 Accra SXT, NAL þ 2 þ dfrA1-sat-aadA1
V40 m 35 Accra SXT, NAL þ 2 þ dfrA1-sat-aadA1
V87 f 24 Adabraka SXT, CRO þ 2 þ dfrA1-sat-aadA1
V95 m 2 Awoshie SXT, CRO 22 2 2
V107 f 37 Agona Swedru SXT, AMP þ 22 2
V98 m 8 Dangbe West SXT, AMP þ 2 þ dfrA1-sat-aadA1
V1388 f 8 Ga West SXT, CTX, CXM þ 2 þ dfrA1-sat-aadA1
V1433 m 6 Accra SXT, CTX, CXM þ 2 þ dfrA1-sat-aadA1
V32 m 29 Ga West SXT, AMP, NAL þ 22 2
V33 m 21 Ga West SXT, AMP, NAL þ 22 2
V53 m 5 Agbogbloshie SXT, AMP, NAL þ 2 þ dfrA1-sat-aadA1
V45 m 28 Agbogbloshie SXT, AMP, CHL þ 2 þ dfrA1-sat-aadA1
V111 f 6 Tema AMK, GEN, NAL 22 2 2
V84 f 25 Madina SXT, AMP, TET, CXM þ 2 þ dfrA1-sat-aadA1
V79 m 9 Weija SXT, AMK, AMP, CHL þ 2 þ dfrA1-sat-aadA1
V89 m 27 Tema SXT, AMK, CAZ, CRO,
GEN, NAL
þ 2 þ dfrA1-sat-aadA1
V85 f 21 Adabraka SXT, AMP, CRO, CTX,
CHL, TET, CXM
þ 2 þ dfrA1-sat-aadA1
V78 m 28 Agbogbloshie SXT, AMP, CAZ, CRO,
CHL, NAL, CXM
þþ þ dfrA1-sat-aadA1
V90 m 7 Agbogbloshie SXT, AMK, CAZ, CRO,
CTX, CHL, GEN,
TET, NAL, CXM
þþ þ dfrA1-sat-aadA1
SXT, trimethoprim/sulfamethoxazole; AMK, amikacin; AMP, ampicillin; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; CHL, chloramphenicol;
GEN, gentamicin; TET, tetracycline; NAL, nalidixic acid; CXM, cefuroxime.
Also tested: levoﬂoxacin.
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demonstrate that multiple elements conferred trimethoprim
resistance on isolates from this 2006 outbreak and that strains
bearing such elements were disseminated through the Accra
metropolis area. Consequently, trimethoprim/sulfamethoxazole
should not be used in cholera treatment in this region.
Tetracycline may be a possible alternative in this regard because
even though studies in the 1970s and 1980s reported resistance,
in this and some other recent studies, susceptibility has been
unexpectedly common.
2,23
Ten of the isolates evaluated were resistant to nalidixic acid.
Quinolones have, until recently, been a fail–safe alternative in
cholera and other diarrhoeal disease epidemics. Our data suggest
that quinolone susceptibility cannot be taken for granted and
therefore this class of drugs is no longer a fail–safe empirical
treatment. Stable trimethoprim resistance coupled with the
appearance of quinolone resistance is worrisome, in that it
further narrows options for empirical antimicrobial therapy and
epidemic control. There is a need to monitor resistance proﬁles
throughout present-day outbreaks and to encourage the
implementation of non-antimicrobial strategies for transmission
control, such as vaccination.
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